Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Renaissance London Heathrow Hotel

10 oct 2018 8:00 a.m. - 11 oct 2018 4:30 p.m.

Bath Road, Hounslow, Middlesex, TW6 2AQ, United Kingdom

2018 European Forum for Qualified Person for Pharmacovigilance (QPPV)

Session 3 Hot Topics – A Regulator’s Perspective

Session Chair(s)

Maarten  Lagendijk, MSc

Maarten Lagendijk, MSc

Deputy EU QPPV

MSD, Netherlands

Menno  Van Der Elst, PharmD, PhD

Menno Van Der Elst, PharmD, PhD

PRAC member

Medicines Evaluation Board, Netherlands

The activities in the Pharmacovigilance Risk Assessment Committee (PRAC) covers a wide range of procedures, and the level of experience has reached a high level of matureness more than 5 years after the 2012 EU pharmacovigilance legislation came into force. For the QPPV it is important to keep abreast with the PRAC activities, and the current session will provide valuable insight into the functioning of the PRAC. Which are the current hot topics the committee is dealing with? Who are the most important stakeholders and how does the PRAC cooperate with them? Answers to these and many more questions will be provided in this session.

Speaker(s)

Doris Irene Stenver, MD, MPA

An update from the Pharmacovigilance Risk Assessment Committee (PRAC)

Doris Irene Stenver, MD, MPA

Unique Advice, Denmark

Independent Pharmacovigilance Adviser

Menno  Van Der Elst, PharmD, PhD

An update from the Pharmacovigilance Risk Assessment Committee (PRAC)

Menno Van Der Elst, PharmD, PhD

Medicines Evaluation Board, Netherlands

PRAC member

Anja  Van Haren, MSc

Anja Van Haren, MSc

Medicines Evaluation Board (MEB), Netherlands

Eudravigilance coordinator

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.